Revance clinical trials

Also known as Crown Laboratories.

Part of Hildred Capital Management, LLC. Source

The registry lists 36 studies whose lead sponsor is Revance or one of 2 companies grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 4, 2025.

Studies

Recruiting first, then most recently updated. Showing 36 of 36.

• Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar LinesCompletedNCT06411002Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• DaxibotulinumtoxinA for Injection for the Management of Plantar FasciitisTerminatedNCT02973269Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• A Proof of Concept Study to Evaluate the Efficacy and Tolerability of Skinpen on Male and Female Subjects' Dorsal Hands as a Treatment of Hand AgingCompletedNCT05030051Not applicable

  Sponsor listed in the registry: Crown Laboratories, Inc.

• Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb SpasticityCompletedNCT03821402Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• DaxibotulinumtoxinA for Injection for the Treatment of Plantar FasciitisCompletedNCT03825315Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar FasciitisCompletedNCT03137407Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial LinesCompletedNCT04259086Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal LinesCompletedNCT03911102Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for VitiligoCompletedNCT05053022Not applicable

  Sponsor listed in the registry: Crown Laboratories, Inc.

• Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)CompletedNCT03786770Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)CompletedNCT03608397Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar LinesCompletedNCT03014635Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar LinesCompletedNCT03014622Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar LinesCompletedNCT03004248Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• A Proof of Concept Study to Evaluate the Efficacy and Tolerability of Microneedling With SkinPen in Female and Male Subjects With Facial Acne Vulgaris, Ages 18 Through 45CompletedNCT05071274Not applicable

  Sponsor listed in the registry: Crown Laboratories, Inc.

• Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)CompletedNCT03617367Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Tolerability of SkinPen on Male and Female Subjects' Wrinkles of the NeckCompletedNCT03803059Not applicable

  Sponsor listed in the registry: Bellus Medical, LLC · First submitted after Bellus Medical, LLC became part of Revance

• Teosyal RHA® Histology and Intradermal Implantation Evaluation StudyStatus unknownNCT04846530

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• A Six Week Topical Cream Study for Subjects With Ichthyosis VulgarisCompletedNCT03173547Phase 2

  Sponsor listed in the registry: Crown Laboratories, Inc.

• SkinPen Efficacy on Acne Scars on the Face and/or BackCompletedNCT02646917Not applicable

  Sponsor listed in the registry: Bellus Medical, LLC · First submitted before Bellus Medical, LLC became part of Revance

• Study to Evaluate the Efficacy and Tolerability of the SkinPen on Male and Female Subjects' Dorsal Hands as a Treatment for Signs of Hand AgingWithdrawnNCT04136847Not applicable

  Sponsor listed in the registry: Bellus Medical, LLC · First submitted after Bellus Medical, LLC became part of Revance

• Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesCompletedNCT00884234Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in AdultsCompletedNCT01064518Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical DystoniaCompletedNCT02706795Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal LinesCompletedNCT02580370Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary HyperhidrosisCompletedNCT02565732Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar LinesCompletedNCT02303002Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet LinesTerminatedNCT01818076Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet LinesCompletedNCT01776606Phase 3

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet LinesCompletedNCT01940991Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in AdultsCompletedNCT01124552Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in AdultsCompletedNCT01124565Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesCompletedNCT00907387Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesCompletedNCT00968825Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesCompletedNCT00888914Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance

• Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesCompletedNCT00968942Phase 2

  Sponsor listed in the registry: Revance Therapeutics, Inc. · First submitted before Revance Therapeutics, Inc. became part of Revance